JAKAFI vs XELJANZ

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 13, 2026·How we rate

Possible drug interaction. JAKAFI and XELJANZ are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	JAKAFI	XELJANZ
Rating	New	64/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RUXOLITINIB PHOSPHATE	TOFACITINIB CITRATE
Manufacturer	Incyte Corp	Pfizer
Dosage forms	Tablet	Solution, Tablet
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Polycythemia Vera, Primary Myelofibrosis	Rheumatoid Arthritis

jakafi xeljanz

Rating

New

64/100

Pharmacy pays

—

Type

Active ingredient

RUXOLITINIB PHOSPHATE

TOFACITINIB CITRATE

Manufacturer

Incyte Corp

Pfizer

Dosage forms

Tablet

Solution, Tablet

Drug class

Janus Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Polycythemia Vera, Primary Myelofibrosis

Rheumatoid Arthritis

Frequently asked questions

What is the difference between Jakafi and Xeljanz?

Jakafi contains Ruxolitinib Phosphate, while Xeljanz contains Tofacitinib Citrate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.